A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases. LINZESS® (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administration, or U.S. FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 296M | 296M | 351M | - | 411M | 414M |
| Net Income | 24M | 24M | 880K | -1.0B | 175M | 528M |
| EPS | $0.15 | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
| Free Cash Flow | 127M | 127M | 103M | 183M | 274M | 262M |
| ROIC | 11.0% | 55.0% | 48.5% | -1117.7% | 26.6% | 38.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -3.00 | -1.94 | -1.73 | 0.61 | 0.94 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 99M | 99M | 93M | -945M | 250M | 232M |
| Operating Margin | 33.3% | 33.3% | 26.5% | - | 61.0% | 56.1% |
| ROE | 0.0% | - | - | - | 26.8% | 87.2% |
| Shares Outstanding | 160M | 160M | 88M | 155M | 182M | 165M |
IRONWOOD PHARMACEUTICALS INC passes 2 of 9 quality checks, indicating weak fundamentals.
IRONWOOD PHARMACEUTICALS INC trades at 26.9x trailing earnings, compared to its 15-year median P/E of 17.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 5.2x vs a median of 7.8x. The company's 5-year average ROIC is 42.1%. At current prices, the estimated annualized return to fair value is +11.5%.
IRONWOOD PHARMACEUTICALS INC (IRWD) has a current P/E ratio of 26.9, compared to its historical median P/E of 17.4. The stock is currently considered Fair based on its historical valuation range.
IRONWOOD PHARMACEUTICALS INC (IRWD) has a 5-year average return on invested capital (ROIC) of 42.1%. This indicates strong capital allocation and a potential competitive advantage.
IRONWOOD PHARMACEUTICALS INC (IRWD) has a market capitalization of $647M. It is classified as a small-cap stock.
IRONWOOD PHARMACEUTICALS INC (IRWD) does not currently pay a regular dividend.
Based on historical P/E analysis, IRONWOOD PHARMACEUTICALS INC (IRWD) appears fair. The current P/E of 26.9 is 55% above its historical median of 17.4. The estimated fair value CAGR (P/E method) is -47.7%.
IRONWOOD PHARMACEUTICALS INC (IRWD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
IRONWOOD PHARMACEUTICALS INC (IRWD) reported annual revenue of $296 million in its most recent fiscal year, based on SEC EDGAR filings.
IRONWOOD PHARMACEUTICALS INC (IRWD) has a net profit margin of 8.1%. This is a modest margin.
IRONWOOD PHARMACEUTICALS INC (IRWD) generated $127 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
IRONWOOD PHARMACEUTICALS INC (IRWD) reported earnings per share (EPS) of $0.15 in its most recent fiscal year.
The Ledger Terminal provides 17 years of financial data for IRONWOOD PHARMACEUTICALS INC (IRWD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IRONWOOD PHARMACEUTICALS INC (IRWD) has a book value per share of $-1.64, based on its most recent annual SEC filing.